Subscribe

Web Exclusives

The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.
Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.
Today, the US Food and Drug Administration (FDA) granted accelerated approval for an oral medication to treat patients with advanced non—small-cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.
The US Food and Drug Administration (FDA) today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).
Over the years, it has become increasingly evident that cancer is a highly heterogeneous disorder. There are a multitude of different tumor types that can affect all organs and organ systems of the body. Because of genetic variations, no 2 tumors are exactly the same.
New York – February 12, 2014 – Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, is proud to be part of the limited Specialty Pharmacy Network of IMBRUVICA™ (ibrutinib).
The FDA recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage).
PharMerica Corporation’s (NYSE: PMC), a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, and Onco360, the largest independent provider of oncology pharmacy services in the United States, today announced that the companies have entered into a definitive agreement under which PharMerica has acquired a significant minority stake of Onco360.
The Office of Civil Rights (OCR) has begun stepping up efforts to ensure that covered entities are in compliance with HIPAA regulations. OCR audits are typically conducted is response to a complaint. In order to be compliant, practices should have policies in place regarding the treatment of all health information containing individually identifiable information. The policy should extend to electronic as well as written information.
Page 3 of 4
Results 21 - 30 of 31
  • American Health and Drug Benefits
  • Association for Value Based Cancer Care
  • Lynx CME
  • Oncology Practice Management
  • Rheumatology Practice Management

Search